Nanoxis Consulting AB
The Lipid-based Protein Immobilization technology (LPI™), developed in collaboration with pharmaceutical and academic groups, enables immobilization of native membrane proteins in the form of proteoliposomes, generated directly from cells or tissue. The technology is based on the use of proprietary surfaces and sample preparation protocols designed to retain the natural environment around the membrane proteins. The membrane proteins can be subjected to a variety of protocols in a highly controlled manner, to provide effective and precise preparation of samples for downstream analysis. LPI™ FlowCell is the first product based on the LPI™ technology and is used in applications such as functional studies, absolute quantification, epitope identification and sequencing studies amongst others. Additional products are in development, where other formats will complement LPI™ FlowCell and allow straightforward expansion of experimental protocols and applications.
High protein sequencing can be achieved with LPI™ FlowCell kits due to the benefit of the flow cell format. Immobilized proteins are sequentially digested with several different enzymes without centrifugation steps using a multi-step protocol and a regular pipette. The peptides are at the same time fractionated and a very high sequence coverage is achieved.
Lennart Torstenssonsgatan 5
400 16 Gothenburg, Sweden
40016 Gothenburg, Sweden